Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 7/20 | 0.33 |
| ▸ | CCR1 | P32246 | 4/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886548 | 0.87 | CAPN1 (0.48) | CAPN1 | |
| SCHEMBL22886634 | 0.78 | PYGL (0.41) | PYGLCAPN1CCR1CNR1CNR2 | |
| SCHEMBL20027478 | 0.77 | PYGL (0.42) | PYGLCAPN1CCR1HPGDS | |
| SCHEMBL22886412 | 0.77 | PYGL (0.42) | PYGLCAPN1CCR1HPGDSCNR1 | |
| SCHEMBL22886411 | 0.77 | PYGL (0.42) | PYGLCAPN1CCR1 | |
| SCHEMBL22885920 | 0.76 | PYGL (0.40) | PYGLCAPN1CCR1CNR1CNR2 | |
| SCHEMBL22886608 | 0.76 | CAPN1 (0.49) | CAPN1 | |
| SCHEMBL22886625 | 0.73 | PYGL (0.44) | PYGLCAPN1HPGDS | |
| SCHEMBL22886021 | 0.73 | CAPN1 (0.49) | CAPN1 | |
| SCHEMBL20028606 | 0.73 | PYGL (0.43) | PYGLCCR1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | PYGL 719/4885CAPN1 3/4885CCR1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.